Core Insights - Teleflex has parted ways with CEO Liam Kelly, appointing Stuart Randle as interim president and CEO while searching for a permanent replacement [3][8] - The leadership change is part of a transformation strategy following the announcement of divesting three business units for approximately $2 billion [5][8] - Teleflex has revised its revenue guidance for 2025 to $3.27 billion to $3.28 billion, down from a previous estimate of $3.31 billion to $3.32 billion, citing softer demand for certain medical devices [7][8] Leadership Changes - Liam Kelly, who became CEO in 2018, has left the company without a permanent successor [3] - Stuart Randle, a board member since 2009 and former CEO of Ivenix, has been appointed as interim president and CEO [4][5] - Stephen Klasko has taken over as chairman of the board following Kelly's departure [3] Business Strategy - Teleflex is in the process of closing the $1.5 billion sale of its OEM business and the $530 million sale of its acute care and interventional urology units [5][6] - The divestitures will allow Teleflex to focus on its vascular access, interventional, and surgical businesses [6] Financial Outlook - The company expects a revenue reduction of just over 1% at the midpoint due to lower-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia [7] - The revised revenue guidance reflects challenges in the OEM business and delays in purchase orders [7]